TABLE 4.
Association between NT-proBNP trajectories and 5-year outcomes.
| Unadjusted | Adjusted model 1a | Adjusted model 2b | Adjusted model 3c | |||||
| HR (95 CI%) | P-value | HR (95 CI%) | P-value | HR (95 CI%) | P-value | HR (95 CI%) | P-value | |
| All-cause mortality | ||||||||
| Class 1 | Ref. | Ref. | Ref. | Ref. | ||||
| Class 2 | 2.303 (1.464–3.622) | <0.01 | 1.887 (1.048–3.398) | 0.03 | 1.924 (1.063–3.483) | 0.03 | 1.902 (1.028–3.519) | 0.04 |
| Class 3 | 6.612 (3.803–11.496) | <0.01 | 6.263 (2.912–13.47) | <0.01 | 6.159 (2.792–13.585) | <0.01 | 5.695 (2.452–13.229) | <0.01 |
| CV mortality | ||||||||
| Class 1 | Ref. | Ref. | Ref. | Ref. | ||||
| Class 2 | 3.448 (1.724–6.895) | <0.01 | 2.481 (1.03–5.977) | 0.04 | 2.653 (1.088–6.47) | 0.03 | 2.295 (0.888–5.933) | 0.09 |
| Class 3 | 8.836 (3.898–20.028) | <0.01 | 7.174 (2.307–22.31) | <0.01 | 7.349 (2.249–24.019) | <0.01 | 4.304 (1.321–14.026) | 0.02 |
| Rehospitalization | ||||||||
| Class 1 | Ref. | Ref. | Ref. | Ref. | ||||
| Class 2 | 0.93 (0.627–1.379) | 0.72 | 0.772 (0.459–1.299) | 0.33 | 0.756 (0.454–1.258) | 0.28 | 0.728 (0.43–1.233) | 0.24 |
| Class 3 | 1.585 (0.861–2.918) | 0.14 | 1.226 (0.551–2.731) | 0.62 | 1.087 (0.494–2.392) | 0.84 | 1.001 (0.438–2.289) | 0.99 |
| CV rehospitalization | ||||||||
| Class 1 | Ref. | Ref. | Ref. | Ref. | ||||
| Class 2 | 1.241 (0.722–2.133) | 0.43 | 1.126 (0.498–2.544) | 0.78 | 1.076 (0.484–2.393) | 0.86 | 0.929 (0.413–2.087) | 0.86 |
| Class 3 | 2.296 (1.056–4.991) | 0.04 | 1.883 (0.613–5.782) | 0.27 | 1.546 (0.511–4.678) | 0.44 | 1.268 (0.397–4.054) | 0.69 |
aModel 1 adjusted for baseline variables including age, sex, body mass index, Society of Thoracic Surgeons score, diabetes, hypertension, chronic obstructive pulmonary disease, estimated glomerular filtration rate, prior stroke, atrial fibrillation/flutter, left ventricular ejection fraction, New York Heart Association class and NT-proBNP levels.
bModel 2 adjusted for baseline variables plus procedural complications including New or aggravated atrioventricular block, vascular complications, annular rupture, coronary obstruction, circulation collapse, aortic regurgitation paravalvular ≥ moderate and aortic regurgitation transvalvular ≥ moderate.
cModel 3 adjusted for baseline variables plus procedural complications plus 30-day post-TAVR outcomes including New York Heart Association ≥ Class III, myocardial infarction, stroke, disabling stroke, bleeding, life threatening bleeding, new permanent pacemaker, new atrial fibrillation, renal dysfunction.